WO2002070594A2 - A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge - Google Patents
A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge Download PDFInfo
- Publication number
- WO2002070594A2 WO2002070594A2 PCT/IB2002/001452 IB0201452W WO02070594A2 WO 2002070594 A2 WO2002070594 A2 WO 2002070594A2 IB 0201452 W IB0201452 W IB 0201452W WO 02070594 A2 WO02070594 A2 WO 02070594A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagen
- sponge
- foam
- tendons
- gel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/36—Surgical swabs, e.g. for absorbency or packing body cavities during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/046—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
- C08H1/06—Macromolecular products derived from proteins derived from horn, hoofs, hair, skin or leather
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00463—Plasters use haemostatic
- A61F2013/00472—Plasters use haemostatic with chemical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the present invention relates to a method of preparing a collagen sponge.
- the collagen sponge produced according to the invention is in particular useful in surgery primarily to stop capillary bleeding.
- the collagen sponge may also be used as a carrier to be coated with a fibrin glue preparation.
- the invention also relates to a device for extracting a part of a collagen foam.
- the invention further relates to an elongated collagen sponge, primarily for gastrointestinal use.
- Collagen has been used as a hemostyptic agent since the late sixties. Collagen is the most frequent structural protein in all mammalians. The monomeric protein of approximately 300 kDa (tropocollagen) is covalently crosslinked at specific sites. The mature protein is therefore insoluble and forms characteristic fibrils with high tensile strength. Numerous sub-classes of collagen have been described, the most common of which is collagen type I, the main collagen type in skin, tendons bones and cornea. Collagen is a fibrous protein consisting substantially of a triple helix with a length of approximately 290 nm. Five of these triple helices (tropocollagen molecules) are staggered to form a microfibril with a diameter of approximately 3.6 nm.
- microfibrils have polar and non-polar segments that are readily accessible for specific inter- and intrafibrillar interactions.
- Microfibrils are packed into a tetragonal lattice to form subfibrils with a diameter of about 30 nm. These subfibrils are then assembled into the collagen fibril, the basic unit of connective tissue, which has a diameter of several hundred nm and is therefore visible in a light microscope as a thin line, see reference 1.
- Collagen gel and collagen sponge as produced during the manufacturing process, comprises these fibrils as the smallest units, as proved by microscopy.
- Collagen may be used as a material for sealing wounds, possibly with a coating comprising a fibrin glue.
- Fibrin glues i.e. the combination of fibrinogen, thrombin and aprotinin have successfully been used therapeutically for many years for gluing tissues and nerves and for sealing surfaces when there is minor bleeding.
- One draw back of the fibrin glues has been that in case of major bleeding the glue is usually washed away before sufficient polymerisation of fibrin has occurred.
- surgeons have manually applied liquid fibrin glues to absorbable carriers such as collagen fleece. Despite the impressive success of these combined applications this method has not been applied on a broad scale, due to some disadvantages.
- the preparation is relatively cumbersome, the method requires experience and skilled personnel, and the preparation is not readily available in cases of emergency, the time for preparation being in the range of 10 to 15 min.
- These factors stimulated the development of an improved product resulting in the development of a fixed combination of a collagen carrier covered with a coating of solid fibrinogen, solid thrombin and solid aprotinin as disclosed in EP 0 059 265.
- the product disclosed in EP 0 059 265 which has been marketed under the trademark TachoComb ® can be applied directly to the wound. When the coating comes into contact with aqueous fluids like blood, other body fluids or saline, the components dissolve and fibrin is formed. The product is applied to the wound with a slight pressure and collagen is tightly bound (glued) to the injured surface. Haemostasis is achieved and the wound is sealed.
- the function of collagen in TachoComb ® is mainly that of a carrier which adsorbs and confers mechanical stability to the coagulation preparation with which it is coated.
- Other advantages of collagen, in particular in the form of a sponge, are its biodegradability, its relatively high tensile strength, even in the wet state, its high resistance against the penetration of liquids and air, and its high flexibility in the wet state.
- the present invention is primarily concerned with the production of a collagen sponge which may be used as a carrier for fibrinogen, thrombin and/or aprotinin, e.g., as in TachoComb ® .
- the collagen sponge may also be used directly, i.e. without a coating, as a bandage on topical injuries, for support of haemostasis, such as for prevention of rebleeding, for weak, diffuse bleeding from parenchymatic organs, for application on burns, skin grafts, decubitus or skin defects, or as a bandage on topical injuries.
- WO 86/05811 discloses a weighted microsponge for immobilizing bioactive materials in motive bioreactor systems, the microsponge comprising a highly cross-linked collagen matrix.
- the highly cross-linked collagen matrix is prepared by milling a source of Type I, II or III collagen to yield fibers having a diameter on the order of 1 to 50 ⁇ m and a length no greater than 200 ⁇ m.
- the milled collagen is formed into a soluble collagen dissolved in a solvent, or an insoluble collagen dispersed in a solvent by admixture with a solvent, such as acetic acid, lactic acid, proprionic acid or butyric acid.
- a collagen dispersion In the case of a collagen dispersion, the mixing is accomplished with a high level of agitation using a blender, so as to produce microfibers of the collagen.
- a weighting additive is blended with the collagen-liquid mixture and the composite mixture is formed into small droplets and solidified by freezing.
- a number of techniques for producing small particles are disclosed.
- the frozen composite is vacuum freeze-dried, the combination of freezing and drying being referred to as lyophilization.
- the freeze-dried collagen matrix composite is treated so as to cross-link the collagen.
- the collagen can be cross-linked using either chemical cross-linking agents, by severe dehydration at an elevated temperature or by a combination.
- the collagen matrix aimed at being resistant to collagenase and other enzymatic degradation thereby making these materials particularly suitable for culturing organisms.
- the microsponges may be sterilized and aseptically packaged.
- the collagen matrix has an open to the surface pore structure with an average pore size in the range of from about 1 to about 150 ⁇ m, the pores of the matrix occupying from about 70 to about 98% by volume of the microsponge.
- the microsponge further has an average particle size of from about 100 to about 1000 ⁇ m and a specific gravity of above about 1.05.
- the weighting material may be metal or alloys from metal, metal oxides and ceramics.
- US 5,660,857 discloses a process for preparing a composite comprising an insoluble protein matrix and an oleaginous material, which is useful as a material for surgical dressings and biomedical implants, and as a cosmetic material for application to the skin.
- the process of US 5,660,857 comprises the steps of mixing a protein, the oleaginous material and water to form an emulsion of the oleaginous material in an aqueous dispersion of the protein, and subsequently drying or freeze-drying the emulsion to form a film or a sponge.
- the insoluble fibrous protein is predominantly comprised of insoluble collagen, which may suitably be obtained from bovine skin. In one embodiment, the collagen may be swollen in lactic acid prior to use.
- WO 99/13902 discloses a method for producing a meningeal tissue growth matrix comprising the step of preparing physiologically compatible collagen which is substantially free of active viruses and prions.
- the collagen is formed into a film, a sponge, a non-woven collagen or a felt.
- the collagen is obtained by a process comprising cleaning skin, tendons, ligaments or bone of fat.
- the material is then subjected to an enzyme treatment, whereby the collagen material is swelled.
- the collagen material is then further swollen with an acid solution.
- the collagen mixture is then homogenised.
- the product obtained may be a matrix provided in the form of a collagen sponge, a non-woven matrix, felt or film, or a composite of two or more of he foregoing forms.
- a collagen sponge can be provided by adaptation of the methods for forming collagen sponges disclosed in US 5,019,087.
- the sponge can be prepared by lyophilization of a collagen dispersion prepared according to WO 99/13902.
- the sponge density achieved is said to be about 0.1 mg/cm 3 to about 120 mg/cm 3 .
- the pore size ranges from about 10 ⁇ m to • about 500 ⁇ m. Laminate type of collagen sponge and collagen film are mentioned.
- US 5,618,551 relates to a non-crosslinked and potentially crosslinkable pepsintreated collagen or gelatin powder modified by oxidative cleavage in an aqueous solution, which is soluble at an acid pH and stable on storage at a temperature of below 0°C for at least one month.
- the patent further relates to a process of preparing the powder, comprising preparing an acidic solution of pepsin-treated collagen, subjecting the acidic aqueous solution at room temperature to controlled oxidation, precipitating the oxidized and noncrosslinked pepsintreated collagen at an acid pH, and isolating, concentrating and dehydrating the noncrosslinked pepsintreated collaged so as to obtain it in the form of a reactive acidic powder, and freezing and storing the obtained reactive acidic powder at a temperature of below 0°C.
- GB 1 292 326 discloses a method and apparatus for the preparation of collagen dispersions with a view to their applications, wherein a suspension of collagen fibres is prepared and subsequently introduced into a treatment chamber with stirring means. A sub-atmospheric pressure exists in the treatment chamber, in which the suspension is transformed into a dispersion by stirring and controlled acidification by means of a mineral or organic acid.
- the preparation of spongy collagenic articles can be effected from dispersion or gels of collagen.
- the documents refers to lyophilization and to dispersion or gels very rich in air bubbles.
- GB 1 292 326 further mentions a problem of controlling the introduction or the elimination of air bubbles in a satisfactory manner.
- the documents discloses, in two examples, a collagenic dispersion free of air bubbles with a collagen content of 2.5%, and an aerated dispersion of collagen with a collagen concentration of 2.5%, respectively.
- the invention provides a method of preparing a collagen sponge, comprising the steps of: - preparing a collagen gel,
- chamber diameter should be understood as the largest straight-line wall-to-wall distance in a chamber, i.e. as the largest diagonal straight-line distance of a chamber.
- the chambers may be of a polygonal shape, such as of an octagonal shape.
- the collagen gel has a dry mass in the range of 2-20 mg dry mass per 1 g gel, such as 4-18 mg, such as 5-13 mg, such as 6-11 mg per 1 g gel.
- the dynamic viscosity of the collagen gel is preferably 2-20 Ncm, such as 4-10 Ncm, such as 6-8 Ncm.
- the collagen sponge preferably has a water content of not more than 20%, such as 10-15%, such as about 18%.
- the elasticity module of the collagen sponge is preferably in the range of 5-100 N/cm, such as 10-50 N/cm, and the density of the sponge is preferably 1-10 mg/cm 3 , such as 2-7 mg/cm 3 .
- a collagen sponge prepared by the method according to the invention is air and liquid tight in the sense that, once the collagen sponge is applied to a wound, it will not allow air or liquid to pass through the collagen sponge. Liquids are absorbed in the sponge. This effect is primarily achieved due to the fact that the step of mixing air into the collagen gel provides a collagen sponge which has a three-dimensional structure with stacked chambers separated and substantially totally enclosed by walls of collagen material, in contradiction to those known collagen sponges which have a fibre structure.
- the collagen gel may comprise material of different types, such as type I, II or III from mammalian, transgenic or recombinant sources, but all other types of collagen can be used.
- the collagen may comprise material from tendons selected from the group consisting of equine tendons, human tendons, and bovine tendons.
- the collagen gel may additionally or alternatively comprise recombinant collagen material.
- the collagen content of the isolated parts of sponge is preferably 50% - 100% related to dry mass of the sponge, such as 75% - 100%, such as 80% - 100%, such as 85% - 100%, such as 90% - 100%, such as 92 - 100%, such as 92 - 98%, such as 93 - 97%, such as 94% - 96%.
- the step of preparing the collagen gel preferably comprises the steps of:
- the steps of storing, peeling, removing protein, reducing of germ content, and swelling aim at purifying the raw material, whereas the step of homogenising aims at obtaining the collagen in the form of a gel.
- the step of reducing of germ content preferably comprises adding an acid, such as an organic acid, such as lactic acid to the tendons.
- an organic solvent such as an alcohol, such as ethanol is preferably added to the tendons.
- the step of swelling of the tendons preferably comprises adding lactic acid to the tendons.
- the lactic acid used may be a 0.40 - 0.50% lactic acid, such as a 0.45% lactic acid.
- the step of swelling of the tendons may comprise storing the tendons at a temperature of 4°C to 25°C, such as a temperature of 10°C to 20°C, for a period of 48 to 200 hours, such as a period of 100 to 200 hours.
- the step of homogenising the swelled tendons is preferably carried out so as to obtain a particle size of collagen gel fragments, i.e. fibre balls, with a diameter of 0.8 - 1.2 cm, such as approximately 1 cm.
- the physical characteristics of the collagen gel are preferably as stated above. The appropriate characteristics may for example be achieved by performing the step of homogenising the swelled tendons by means of a toothed disk mill or adequate homogenisation equipment.
- the step of mixing air into the collagen gel preferably comprises the steps of:
- At least some of the collagen gel separated from the collagen foam in the fractionising channel may be led back to the mixer.
- the ratio between the amount of collagen gel which is led back to the mixer from the fractionising channel and the amount of fresh collagen gel led to the mixer is preferably between 0.1 and 0.5.
- the step of separating collagen gel and collagen foam preferably comprises the steps of:
- a temperature of 15°C to 40°C, such as 20°C to 20 25°C is maintained in the fractionising channel.
- the collagen foam may be homogenised for a period of 2 to 4 minutes.
- a neutraliser may be added to the collagen foam, and the collagen foam is preferably neutralised in order to arrive from a pH-value of, usually, between 2.5 and 3.5 to a pH-value in the collagen foam between 6.5 and 8.5.
- a neutraliser comprising an ammonia solution may be used, and the collagen foam is preferably neutralised for a
- the collagen foam Prior to the step of drying the collagen foam, the collagen foam is preferably filled into a drying container in such a way that substantially no air is drawn into the foam while filling.
- the step of drying preferably comprises drying at a temperature between 15°C and 60°C, such as between 20° and 40°C, for a period of 50-200 hours, such as 100-150 hours, so as to obtain a dry collagen sponge.
- the drying may be performed at a pressure slightly under atmospheric pressure, such as at a pressure of between 700 and 900 mbar, such as approximately 800 mbar.
- the collagen sponge produced by the method according to the invention preferably fulfils at least one of the following criteria:
- the step of isolating parts of collagen sponge may comprise dividing the collagen sponge into a plurality of parts by cutting.
- the parts obtained may be shaped in any desirable form, such as conical, cylindrical, including cylindrical with an annular cross-section, rectangular, polygonal, cubic, and flat sheets or they may be transformed into a granulate by an appropriate granulating method etc.
- the present invention relates to a method of preparing a collagen sponge, comprising the steps of:
- - elasticity module in the range of 5 to 100 N/cm, - density in the range of 1 to 10 mg/cm 3 ,
- the present invention provides a device for extracting a part of a collagen foam and for degenerating another part of the collagen foam to a collagen gel, comprising:
- fractionising channel comprising an inlet for receiving a flow of collagen foam, an outlet for a part of the flow of collagen foam, and a bottom portion which is inclined downwards in the direction of the flow of collagen foam
- the present invention provides an elongated collagen sponge having a through-going hole or bore and a flexible wall.
- a collagen sponge may be used closing wounds or re-establishing gastrointestinal funnel and trachea walls in mammalians.
- the collagen sponge may have circular or elliptical cross- section.
- the collagen sponge may be applied both as a filling, or as in a gastrointestinal funnel, or as an outer sleeve applied to an outer surface of a gastrointestinal funnel.
- the inner diameter of the through-going hole or bore may, for application in various human gastrointestinal funnels and trachea, for example be as follows:
- Oesophagus 0.5 - 2 cm
- the collagen sponge may, e.g., be used for closing wounds after surgical removal of outpouchings on gastrointestinal funnel walls, such as after rectal surgery, such as after surgical removal of hemorrhoids.
- Examples of indications made possible by the collagen sponge according to the invention are: - wound dressing,
- haemostasis such as
- Figs. 1 and 2 contain a flow chart illustrating the steps involved in a preferred embodiment of the method according to the invention
- Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. réelle Erlangen, Germany), and
- Fig. 4 discloses a stirring device for obtaining a measure of the viscosity of a collagen gel.
- the invention comprises the following steps as illustrated in Figs. 1 and 2:
- Step 1 Delivery of deep-frozen horse tendons
- the horse tendons are delivered and stored at -18 °C to -25 °C.
- the thin skin of the tendons is manually or mechanically removed with a knife.
- the tendons are then again deep-frozen at -18 °C to -25 °C.
- Step 3 Mechanical slicing of peeled horse tendons
- peeled frozen tendons are disinfected for 30 min in 70 % ethanol and passed into production rooms under ethanol.
- the tendons are then washed, and after washing the tendons are compacted to blocks and deep frozen at -18 °C to -25 °C.
- the frozen tendon blocks are then sliced with a cutting machine with a rotating knife into slices having a thickness of approximately 1 mm.
- Step 4 Washing and disinfection of the tendon slices
- the tendon slices are first soaked in water for injection for 3 - 6 hours, then washed with water for injection or demineralized water or salt solutions containing Ca 2+ and/or Mg 2+ -ion within the range of 1-lOmM until the supernatant is free of hemoglobin.
- the tendon slices are then disinfected in 70 % ethanol for 15 min and washed twice in 0.45 % lactic acid in drinking water (sterile filtered and depyrogenised) to remove the ethanol.
- the washed tendon slices are soaked in 0.45 % lactic acid for 2-5 days, preferably 4 days, and then homogenised to a collagen gel. Exposure to 0.45 % lactic acid is considered to be one of the main virus inactivation steps.
- the foam is dried in warm air in a high grade steel drying chamber for 48 - 150 hours, preferably 120 - 150 hours.
- the result is collagen sponge shaped in blocks.
- Blocks, also referred to as sheets, of collagen may for example be used as carriers for a coating.
- the cutting is performed with a vertical cutting machine. First, the sides of the block are cut off to yield a block with vertical sides with a side length of 50 cm. This block is then cut vertically into 4 bars with a width of 11 cm. The bars are again trimmed at their upper and their lower side and then sliced into strips with dimensions of 50 x 11 x 0.4 - 0.7 cm.
- the weight of the collagen sponge strips preferably takes into account any specification of collagen in the final product to be achieved, such as TachoComb ® H, TachoComb ® and Tachotop ® .
- Step 9 Sorting the collagen sponge strips The collagen sponge strips are then subjected to a visual control. Strips with one or more of the following defects are discarded:
- the sorted strips are stored for maximally 1 year in disinfected light metal containers at a temperature of 15 - 25 °C.
- Fig. 3 is a photography of the surface of a collagen sponge produced by a method according to the invention, the photography being taken at a magnification factor of approximately 20,000 (courtesy Prof. Dr. Roman Carbon, Chirurgische Univ. réelle Er Weg, Germany).
- the surface shown in the photography of Fig. 3 is a surface of a cross-sectional cut in a collagen sponge prepared by a method according to the present invention.
- the dark areas in the photography represent chambers, while the light areas in the photography represent collagen material, including walls of collagen material separating the chambers.
- Fig. 4 shows a stirring device for obtaining a measure of a viscosity of a liquid, comprising a container adapted to accommodate a liquid and means for stirring said liquid.
- the stirring means comprise a rod attached to a fork shaped element.
- a liquid in the container is stirred by applying a torque to the rod, resulting in a rotational movement of the fork shaped element.
- the fork shaped element comprises a primary part 41 to which the rod is attached and a first and a second secondary part 42.
- the secondary parts are attached to the ends of the primary part As the fork shaped element rotates the surfaces moves the liquid and thus stirs the liquid.
- the device has the following dimensions.
- the container is 110 mm high and 146 mm wide.
- the rod is 220 mm high and has a diameter of 10 mm.
- the primary part 41 of the fork is 90 mm long and 30 mm high.
- the secondary parts 42 are 90 mm high and 30 mm wide. The distance from an outer edge of the secondary parts 42 to an inner surface of the container is 28 mm.
- Table I below shows parameter values of three different cycles of the method according to the invention.
- Table I Table II below shows parameter values of three different collagen sponges obtained by the method according to the invention.
- This example relates to the indirect measurement of the viscosity of the collagen gel by torque measurement.
- the equipment used for the torque measurement is: - Stirring machine: EUROSTAR POWER control-vise
Abstract
Description
Claims
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1036-2003A SK287874B6 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and en elongated collagen sponge |
AT02718481T ATE310044T1 (en) | 2001-01-25 | 2002-01-25 | METHOD FOR PRODUCING A COLLAGEN SPONGE; EXTRACTION DEVICE OF PART OF A COLLAGEN SPONGE AND EXTENDED COLLAGEN SPONGE |
DE60207389T DE60207389T2 (en) | 2001-01-25 | 2002-01-25 | METHOD FOR PRODUCING A COLLAGEN SPONGE; EXTRACTION DEVICE OF A PART OF A COLLAGEN SPONGE AND EXTENDED COLLAGEN SPONGE |
UA2003087939A UA73028C2 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge (variants), a device for extracting a part of a collagen foam and an elongated collagen sponge |
EP02718481A EP1368419B1 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
HU0303893A HU228810B1 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
JP2002570628A JP4104462B2 (en) | 2001-01-25 | 2002-01-25 | Method for preparing collagen sponge, apparatus for extracting part of collagen foam, and elongated collagen sponge |
CA002435159A CA2435159C (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge |
SI200230251T SI1368419T1 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
BRPI0206705A BRPI0206705B8 (en) | 2001-01-25 | 2002-01-25 | method for preparing a collagen sponge. |
AU2002249528A AU2002249528B2 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
MXPA03006687A MXPA03006687A (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge. |
IL15709602A IL157096A0 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
NZ527166A NZ527166A (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
KR1020037009893A KR100847417B1 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
EEP200300349A EE05587B1 (en) | 2001-01-25 | 2002-01-25 | A method for making collagen |
EA200300821A EA005697B1 (en) | 2001-01-25 | 2002-01-25 | A method for preparing a collagen sponge |
DK02718481T DK1368419T3 (en) | 2001-01-25 | 2002-01-25 | Process for producing a collagen sponge, a device for extracting a portion of a collagen foam and an elongated collagen sponge |
NO20033295A NO332462B1 (en) | 2001-01-25 | 2003-07-22 | Process for making a collagen sponge. |
IL157096A IL157096A (en) | 2001-01-25 | 2003-07-24 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam and an elongated collagen sponge |
BG108122A BG66343B1 (en) | 2001-01-25 | 2003-08-21 | A method of preparing a collagen sponge |
HK04101070A HK1058371A1 (en) | 2001-01-25 | 2004-02-16 | A method of preparing a collagen songe, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200100135 | 2001-01-25 | ||
DKPA200100135 | 2001-01-25 | ||
DKPA200100235 | 2001-02-13 | ||
DKPA200100235 | 2001-02-13 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002070594A2 true WO2002070594A2 (en) | 2002-09-12 |
WO2002070594A3 WO2002070594A3 (en) | 2003-01-03 |
WO2002070594A8 WO2002070594A8 (en) | 2004-03-11 |
Family
ID=26068956
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/001453 WO2002058749A2 (en) | 2001-01-25 | 2002-01-25 | Carrier with solid fibrinogen and solid thrombin |
PCT/IB2002/001452 WO2002070594A2 (en) | 2001-01-25 | 2002-01-25 | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
PCT/IB2002/001454 WO2002058750A2 (en) | 2001-01-25 | 2002-01-25 | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/001453 WO2002058749A2 (en) | 2001-01-25 | 2002-01-25 | Carrier with solid fibrinogen and solid thrombin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/001454 WO2002058750A2 (en) | 2001-01-25 | 2002-01-25 | A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
Country Status (37)
Country | Link |
---|---|
EP (4) | EP1343542B1 (en) |
JP (4) | JP4535678B2 (en) |
KR (2) | KR100830294B1 (en) |
CN (3) | CN1290907C (en) |
AR (3) | AR032517A1 (en) |
AT (2) | ATE310044T1 (en) |
AU (3) | AU2002255220B2 (en) |
BG (3) | BG66439B1 (en) |
BR (3) | BRPI0206709B8 (en) |
CA (3) | CA2434964C (en) |
CL (1) | CL2015003111A1 (en) |
CR (1) | CR7034A (en) |
CZ (3) | CZ304357B6 (en) |
DE (2) | DE60203364T2 (en) |
DK (2) | DK1343542T3 (en) |
EA (4) | EA006686B1 (en) |
EE (3) | EE05587B1 (en) |
EG (2) | EG26417A (en) |
ES (2) | ES2238569T3 (en) |
HK (2) | HK1058319A1 (en) |
HR (1) | HRP20030648B1 (en) |
HU (3) | HU227987B1 (en) |
IL (6) | IL157097A0 (en) |
IS (1) | IS6885A (en) |
ME (1) | ME00587A (en) |
MX (3) | MXPA03006688A (en) |
NO (3) | NO332462B1 (en) |
NZ (3) | NZ527166A (en) |
PL (3) | PL206197B1 (en) |
PT (1) | PT1343542E (en) |
RS (1) | RS50866B (en) |
SI (2) | SI1343542T1 (en) |
SK (3) | SK287874B6 (en) |
TW (2) | TWI237573B (en) |
UA (1) | UA73028C2 (en) |
UY (1) | UY27136A1 (en) |
WO (3) | WO2002058749A2 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8092820B2 (en) | 2001-07-17 | 2012-01-10 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
WO2012159635A1 (en) | 2011-05-24 | 2012-11-29 | Nycomed Pharma As | Rolled collagen carrier |
US8357378B2 (en) | 1996-08-27 | 2013-01-22 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
WO2013174879A1 (en) | 2012-05-24 | 2013-11-28 | Takeda Nycomed As | Packaging |
WO2013174874A1 (en) | 2012-05-24 | 2013-11-28 | Takeda Nycomed As | Apparatus and process for providing a coiled collagen carrier |
US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
US8703122B2 (en) | 2006-05-31 | 2014-04-22 | Baxter International Inc. | Method for directed cell in-growth and controlled tissue regeneration in spinal surgery |
US8703170B2 (en) | 2010-04-07 | 2014-04-22 | Baxter International Inc. | Hemostatic sponge |
US8771258B2 (en) | 2009-12-16 | 2014-07-08 | Baxter International Inc. | Hemostatic sponge |
US8790698B2 (en) | 2007-10-30 | 2014-07-29 | Baxter International Inc. | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
US8834864B2 (en) * | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US8940335B2 (en) | 2010-06-01 | 2015-01-27 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US8962025B2 (en) | 2006-08-02 | 2015-02-24 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US9005609B2 (en) | 2003-08-07 | 2015-04-14 | Ethicon, Inc. | Hemostatic compositions containing sterile thrombin |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9162006B2 (en) | 2009-06-16 | 2015-10-20 | Baxter International Inc. | Hemostatic sponge |
US9408945B2 (en) | 2010-06-01 | 2016-08-09 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9439999B2 (en) | 2011-07-28 | 2016-09-13 | Harbin Peiqilong Biopharmaceutical Co., Ltd | Composite collagen sponge and preparation method thereof |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9821025B2 (en) | 2011-10-11 | 2017-11-21 | Baxter International Inc. | Hemostatic compositions |
US9833541B2 (en) | 2011-10-27 | 2017-12-05 | Baxter International Inc. | Hemostatic compositions |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US10322170B2 (en) | 2011-10-11 | 2019-06-18 | Baxter International Inc. | Hemostatic compositions |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020131933A1 (en) * | 1996-01-16 | 2002-09-19 | Yves Delmotte | Biopolymer membrane and methods for its preparation |
US7279177B2 (en) | 2002-06-28 | 2007-10-09 | Ethicon, Inc. | Hemostatic wound dressings and methods of making same |
US7252837B2 (en) | 2002-06-28 | 2007-08-07 | Ethicon, Inc. | Hemostatic wound dressing and method of making same |
AU2003277833A1 (en) * | 2002-11-04 | 2004-06-07 | Nycomed Danmark Aps | Coating of a particulate material with an organic solvent-based coating composition |
KR101213460B1 (en) | 2003-01-20 | 2012-12-20 | 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 | Hemostatic materials |
DE602004025217D1 (en) | 2003-04-04 | 2010-03-11 | Tissuemed Ltd | |
US20040265371A1 (en) | 2003-06-25 | 2004-12-30 | Looney Dwayne Lee | Hemostatic devices and methods of making same |
US7186684B2 (en) | 2003-08-07 | 2007-03-06 | Ethicon, Inc. | Hemostatic device containing a protein precipitate |
MX2007001554A (en) | 2004-08-03 | 2007-04-10 | Tissuemed Ltd | Tissue-adhesive materials. |
CN101137402B (en) | 2004-10-20 | 2012-01-11 | 伊西康公司 | Reinforced absorbable multilayered fabric for use in medical devices and its preparation thereof |
BRPI0516764B8 (en) * | 2004-10-20 | 2021-05-25 | Ethicon Inc | hemostat |
US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
KR20060040329A (en) * | 2004-11-05 | 2006-05-10 | 나건 | Hemostatic agent which can be applied via endoscope and applying method of the same |
ES2427565T3 (en) | 2005-04-25 | 2013-10-31 | Massachusetts Institute Of Technology | Self-assembling peptides to promote hemostasis |
JP4864348B2 (en) * | 2005-05-27 | 2012-02-01 | 川澄化学工業株式会社 | Nerve regeneration tube |
CA2640629A1 (en) | 2006-02-03 | 2007-08-09 | Tissuemed Limited | Tissue-adhesive materials |
AU2007215382B2 (en) | 2006-02-14 | 2013-11-14 | Commonwealth Scientific And Industrial Research Organisation | Joining and/or sealing tissues through photo-activated cross-linking of matrix proteins |
EP2012842B1 (en) | 2006-04-25 | 2018-04-04 | Massachusetts Institute of Technology | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions |
WO2008019126A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Process for production of solid wound dressing |
GB0623607D0 (en) | 2006-11-27 | 2007-01-03 | Haemostatix Ltd | Tissue adhesive |
CN101053679B (en) * | 2007-04-17 | 2010-05-26 | 浙江大学 | Method for preparing polymer multiporous holder filled with fiber protein gel |
DE102007037056A1 (en) | 2007-07-24 | 2009-01-29 | Aesculap Ag | Hemostyptic made of freeze-dried collagen, useful e.g. to increase absorption capacity of liquids, preferably blood and treat blood vessel leakage, comprises a water-soluble biocompatible organic acid, preferably hydroxyl carboxylic acid |
DE102007037053A1 (en) | 2007-07-24 | 2009-01-29 | Aesculap Ag | Hemostatic for minimally invasive surgery |
DE102007045066A1 (en) | 2007-09-20 | 2009-04-02 | Mike Ehrlich | Hemostatic material containing synthetic peptides or polysaccharides |
DE102007000574A1 (en) | 2007-10-25 | 2009-04-30 | FILK Forschungsinstitut für Leder- und Kunstbahnen gGmbH | Biologically absorbable sponge material, useful in medicine, pharmacy, cosmetics and food area, comprises a collagen-gelatin-mixture or collagen-gelatin-mixture with additives, preferably softener and/or a substance |
CN101214391B (en) * | 2007-12-27 | 2010-05-19 | 广州倍绣生物技术有限公司 | High-efficiency biogum sealant and uses thereof |
US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
WO2010002435A2 (en) * | 2008-07-03 | 2010-01-07 | Kulinets Irina B | Hemostatic pouch and method to stabilize hemostatic components |
EP3470093B1 (en) | 2008-10-06 | 2020-08-19 | 3-D Matrix Ltd. | Tissue plug |
US9271925B2 (en) | 2013-03-11 | 2016-03-01 | Bioinspire Technologies, Inc. | Multi-layer biodegradable device having adjustable drug release profile |
EP2477617B1 (en) | 2009-09-18 | 2018-01-31 | Bioinspire Technologies Inc. | Free-standing biodegradable patch |
WO2011072482A1 (en) | 2009-12-14 | 2011-06-23 | The University Of Hong Kong | Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells |
CA2787883C (en) | 2010-01-28 | 2019-02-19 | Erez Ilan | Method for improved fibrin sealing |
US20130183366A1 (en) * | 2010-07-20 | 2013-07-18 | The Chemo-Sero-Therapeutic Research Institute | Sheet preparation for tissue adhesion |
RU2013155713A (en) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | COMPOSITIONS FOR TREATMENT OF THE RAS |
US20130041406A1 (en) * | 2011-08-10 | 2013-02-14 | Brian W. Bear | Surgical staple with localized adjunct coating |
EP2556842A1 (en) | 2011-08-11 | 2013-02-13 | Bioftalmik, S.L. | Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof |
TWI584825B (en) * | 2012-05-14 | 2017-06-01 | 帝人股份有限公司 | Formed sheet product and hemostatic material |
EP2869903B1 (en) | 2012-07-06 | 2018-11-28 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
DE102013004420A1 (en) | 2012-08-20 | 2014-02-20 | Alexander Kopp | Support body and method for its production |
CA2893064C (en) * | 2012-12-07 | 2021-05-04 | Baxter International Inc. | Hemostatic foam |
KR101401944B1 (en) | 2012-12-11 | 2014-05-30 | 세원셀론텍(주) | Tissue sealant of collagen and fibrin mixed and method of manufacturing the same |
US10765774B2 (en) | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
JP6684719B2 (en) | 2014-03-10 | 2020-04-22 | 株式会社スリー・ディー・マトリックス | Sterilization and filtration of peptide compositions |
CA2939696C (en) | 2014-03-10 | 2023-01-10 | 3-D Matrix, Ltd. | Self-assembling peptide compositions |
ES2712608T3 (en) | 2014-03-10 | 2019-05-14 | 3 D Matrix Ltd | Self-assembling peptides for the treatment of pulmonary bullae |
WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
CN106267328B (en) * | 2016-09-20 | 2019-04-12 | 安徽思维特生物科技有限公司 | A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel |
CN106730031A (en) * | 2016-12-30 | 2017-05-31 | 清华大学 | A kind of bionic fiber protein hydrogel beam repaired for spinal cord injury and preparation method thereof |
EP3723726A1 (en) | 2017-12-15 | 2020-10-21 | 3-D Matrix, Ltd. | Surfactant peptide nanostructures and uses in drug delivery |
RU2679616C1 (en) * | 2018-07-02 | 2019-02-12 | Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Method for preparing a thrombofibrin clot with growth-stimulating properties |
US20220016311A1 (en) * | 2018-12-14 | 2022-01-20 | Bmg Incorporated | Two-reactant sheet-shaped adhesive/reinforcement for tissues |
CN112225937B (en) * | 2020-10-14 | 2022-11-01 | 中山大学 | Temperature-sensitive macroporous biological hydrogel and preparation method and application thereof |
CN113117158B (en) * | 2021-03-10 | 2022-07-26 | 复旦大学 | Material for biological functional modification of surface denatured protein and preparation method and application thereof |
CN114177346B (en) * | 2021-12-24 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | Hemostatic composition and hemostatic patch and application thereof |
CN114246974B (en) * | 2021-12-24 | 2023-11-03 | 中国人民解放军军事科学院军事医学研究院 | Preparation method of hemostatic patch |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1292326A (en) * | 1968-11-27 | 1972-10-11 | Ct Tech Du Cuir | Method and apparatus for the preparation of collagen dispersions with a view to their applications |
US4626286A (en) * | 1983-10-31 | 1986-12-02 | Schmid Laboratories, Inc. | Collagen gel and the process of making said gel |
FR2668936A1 (en) * | 1990-11-09 | 1992-05-15 | Eberlin Jean Luc | Graft based on collagen and fibrin adhesive for osseocartilaginous reconstruction, and method for its preparation |
EP0578823A1 (en) * | 1991-04-08 | 1994-01-19 | Sumitomo Pharmaceuticals Company, Limited | Porous solid preparation containing physiologically active protein substance |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3105624A1 (en) * | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
BR8102435A (en) * | 1981-04-15 | 1982-11-30 | Campos Vidal Benedicto | MICROFIBRILLARY AND MICRO CRYSTALLINE COLLAGEN FOR MEDICINE AND PHARMACY APPLICATION |
DE3214337C2 (en) * | 1982-04-19 | 1984-04-26 | Serapharm - Michael Stroetmann, 4400 Münster | Resorbable flat material for sealing and healing wounds and processes for their manufacture |
US5318524A (en) * | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
AT410754B (en) * | 1993-03-31 | 2003-07-25 | Nycomed Austria Gmbh | DEVICE FOR EVENLY APPLYING A SUSPENSION TO A COLLAGE CARRIER |
US6177126B1 (en) * | 1993-03-31 | 2001-01-23 | Nycomed Arzneimittel Gmbh | Process for the production of a material for sealing and healing wounds |
JPH0759812A (en) * | 1993-08-27 | 1995-03-07 | Koken Co Ltd | Wound cover material and its production |
CN1159206A (en) * | 1994-09-02 | 1997-09-10 | 纽约血库公司 | Production and secretion of recombinant fibrinogen by yeast |
WO1997028832A1 (en) * | 1996-02-06 | 1997-08-14 | New Generation Medical Corporation | Composition for sealing wounds |
HUP9903586A3 (en) * | 1996-04-04 | 2003-02-28 | Baxter Ag | Hemostatic sponge based on collagen |
CA2330972C (en) * | 1998-05-01 | 2008-08-19 | Zymogenetics, Inc. | Fully recombinant tissue sealant compositions |
CA2295609C (en) * | 1998-05-19 | 2009-09-29 | The American National Red Cross | Hemostatic sandwich bandage |
WO2000009018A1 (en) * | 1998-08-10 | 2000-02-24 | Fibrogen, Inc. | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
WO2000038752A1 (en) * | 1998-12-23 | 2000-07-06 | Aventis Behring Gmbh | Fibrin-based glue granulate and corresponding production method |
DE19922078A1 (en) * | 1999-05-15 | 2000-11-23 | Weitzel Kage Doris | Tissue construct for transplant surgery |
-
2002
- 2002-01-25 TW TW091101277A patent/TWI237573B/en not_active IP Right Cessation
- 2002-01-25 EA EA200300822A patent/EA006686B1/en not_active IP Right Cessation
- 2002-01-25 NZ NZ527166A patent/NZ527166A/en not_active IP Right Cessation
- 2002-01-25 EP EP02724554A patent/EP1343542B1/en not_active Expired - Lifetime
- 2002-01-25 AT AT02718481T patent/ATE310044T1/en active
- 2002-01-25 BR BRPI0206709A patent/BRPI0206709B8/en not_active IP Right Cessation
- 2002-01-25 ES ES02724554T patent/ES2238569T3/en not_active Expired - Lifetime
- 2002-01-25 EA EA200300821A patent/EA005697B1/en not_active IP Right Cessation
- 2002-01-25 EA EA200300823A patent/EA006700B1/en not_active IP Right Cessation
- 2002-01-25 AT AT02724554T patent/ATE291445T1/en active
- 2002-01-25 CN CNB028040953A patent/CN1290907C/en not_active Expired - Lifetime
- 2002-01-25 SI SI200230138T patent/SI1343542T1/en unknown
- 2002-01-25 HU HU0303896A patent/HU227987B1/en unknown
- 2002-01-25 DE DE60203364T patent/DE60203364T2/en not_active Expired - Lifetime
- 2002-01-25 CN CNB02804097XA patent/CN1246047C/en not_active Expired - Fee Related
- 2002-01-25 MX MXPA03006688A patent/MXPA03006688A/en active IP Right Grant
- 2002-01-25 UA UA2003087939A patent/UA73028C2/en unknown
- 2002-01-25 HU HU0303893A patent/HU228810B1/en unknown
- 2002-01-25 KR KR1020037009899A patent/KR100830294B1/en active IP Right Grant
- 2002-01-25 TW TW091101272A patent/TWI255726B/en not_active IP Right Cessation
- 2002-01-25 BR BRPI0206705A patent/BRPI0206705B8/en not_active IP Right Cessation
- 2002-01-25 SK SK1036-2003A patent/SK287874B6/en not_active IP Right Cessation
- 2002-01-25 SK SK1035-2003A patent/SK288120B6/en not_active IP Right Cessation
- 2002-01-25 JP JP2002559084A patent/JP4535678B2/en not_active Expired - Lifetime
- 2002-01-25 CN CNB028040961A patent/CN1264578C/en not_active Expired - Lifetime
- 2002-01-25 CZ CZ2003-2197A patent/CZ304357B6/en not_active IP Right Cessation
- 2002-01-25 EE EEP200300349A patent/EE05587B1/en unknown
- 2002-01-25 IL IL15709702A patent/IL157097A0/en unknown
- 2002-01-25 DK DK02724554T patent/DK1343542T3/en active
- 2002-01-25 KR KR1020037009893A patent/KR100847417B1/en active IP Right Grant
- 2002-01-25 JP JP2002559083A patent/JP2004521115A/en active Pending
- 2002-01-25 EA EA200401463A patent/EA006540B1/en not_active IP Right Cessation
- 2002-01-25 WO PCT/IB2002/001453 patent/WO2002058749A2/en active IP Right Grant
- 2002-01-25 AU AU2002255220A patent/AU2002255220B2/en active Active
- 2002-01-25 PL PL366932A patent/PL206197B1/en unknown
- 2002-01-25 DK DK02718481T patent/DK1368419T3/en active
- 2002-01-25 AR ARP020100258A patent/AR032517A1/en active IP Right Grant
- 2002-01-25 EE EEP200300341A patent/EE05685B1/en not_active IP Right Cessation
- 2002-01-25 NZ NZ527165A patent/NZ527165A/en not_active IP Right Cessation
- 2002-01-25 PT PT02724554T patent/PT1343542E/en unknown
- 2002-01-25 PL PL363274A patent/PL205181B1/en unknown
- 2002-01-25 CA CA002434964A patent/CA2434964C/en not_active Expired - Lifetime
- 2002-01-25 EP EP02718481A patent/EP1368419B1/en not_active Expired - Lifetime
- 2002-01-25 RS YUP-670/03A patent/RS50866B/en unknown
- 2002-01-25 BR BRPI0206708A patent/BRPI0206708B8/en not_active IP Right Cessation
- 2002-01-25 SK SK1034-2003A patent/SK10342003A3/en not_active Application Discontinuation
- 2002-01-25 UY UY27136A patent/UY27136A1/en not_active IP Right Cessation
- 2002-01-25 ME MEP-24/09A patent/ME00587A/en unknown
- 2002-01-25 AU AU2002307809A patent/AU2002307809B2/en not_active Expired
- 2002-01-25 PL PL363275A patent/PL206194B1/en unknown
- 2002-01-25 IL IL15709602A patent/IL157096A0/en active IP Right Grant
- 2002-01-25 WO PCT/IB2002/001452 patent/WO2002070594A2/en active IP Right Grant
- 2002-01-25 HU HU0400768A patent/HUP0400768A3/en unknown
- 2002-01-25 EP EP05075501A patent/EP1547626A3/en not_active Withdrawn
- 2002-01-25 WO PCT/IB2002/001454 patent/WO2002058750A2/en active IP Right Grant
- 2002-01-25 EP EP02734886A patent/EP1359947A2/en not_active Ceased
- 2002-01-25 AU AU2002249528A patent/AU2002249528B2/en not_active Expired
- 2002-01-25 CZ CZ20032199A patent/CZ20032199A3/en unknown
- 2002-01-25 AR ARP020100259A patent/AR032400A1/en active IP Right Grant
- 2002-01-25 DE DE60207389T patent/DE60207389T2/en not_active Expired - Lifetime
- 2002-01-25 MX MXPA03006687A patent/MXPA03006687A/en active IP Right Grant
- 2002-01-25 SI SI200230251T patent/SI1368419T1/en unknown
- 2002-01-25 CA CA2435425A patent/CA2435425C/en not_active Expired - Lifetime
- 2002-01-25 ES ES02718481T patent/ES2253523T3/en not_active Expired - Lifetime
- 2002-01-25 IL IL15709502A patent/IL157095A0/en unknown
- 2002-01-25 CZ CZ2003-2198A patent/CZ305120B6/en not_active IP Right Cessation
- 2002-01-25 NZ NZ527167A patent/NZ527167A/en not_active IP Right Cessation
- 2002-01-25 AR ARP020100260A patent/AR032800A1/en not_active Application Discontinuation
- 2002-01-25 MX MXPA03006689A patent/MXPA03006689A/en active IP Right Grant
- 2002-01-25 EE EEP200300348A patent/EE05678B1/en unknown
- 2002-01-25 JP JP2002570628A patent/JP4104462B2/en not_active Expired - Lifetime
- 2002-01-25 CA CA002435159A patent/CA2435159C/en not_active Expired - Lifetime
- 2002-01-26 EG EG2002010097A patent/EG26417A/en active
- 2002-01-26 EG EG20020095A patent/EG24589A/en active
-
2003
- 2003-07-22 NO NO20033295A patent/NO332462B1/en not_active IP Right Cessation
- 2003-07-22 NO NO20033297A patent/NO20033297L/en not_active Application Discontinuation
- 2003-07-22 NO NO20033296A patent/NO327386B1/en not_active IP Right Cessation
- 2003-07-23 CR CR7034A patent/CR7034A/en unknown
- 2003-07-24 IS IS6885A patent/IS6885A/en unknown
- 2003-07-24 IL IL157097A patent/IL157097A/en not_active IP Right Cessation
- 2003-07-24 IL IL157095A patent/IL157095A/en active IP Right Grant
- 2003-07-24 IL IL157096A patent/IL157096A/en unknown
- 2003-08-12 HR HR20030648A patent/HRP20030648B1/en not_active IP Right Cessation
- 2003-08-21 BG BG108123A patent/BG66439B1/en unknown
- 2003-08-21 BG BG108121A patent/BG66420B1/en unknown
- 2003-08-21 BG BG108122A patent/BG66343B1/en unknown
-
2004
- 2004-02-16 HK HK04101068A patent/HK1058319A1/en not_active IP Right Cessation
- 2004-02-16 HK HK04101070A patent/HK1058371A1/en not_active IP Right Cessation
-
2007
- 2007-03-01 JP JP2007051088A patent/JP2007190399A/en active Pending
-
2015
- 2015-10-21 CL CL2015003111A patent/CL2015003111A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1292326A (en) * | 1968-11-27 | 1972-10-11 | Ct Tech Du Cuir | Method and apparatus for the preparation of collagen dispersions with a view to their applications |
US4626286A (en) * | 1983-10-31 | 1986-12-02 | Schmid Laboratories, Inc. | Collagen gel and the process of making said gel |
FR2668936A1 (en) * | 1990-11-09 | 1992-05-15 | Eberlin Jean Luc | Graft based on collagen and fibrin adhesive for osseocartilaginous reconstruction, and method for its preparation |
EP0578823A1 (en) * | 1991-04-08 | 1994-01-19 | Sumitomo Pharmaceuticals Company, Limited | Porous solid preparation containing physiologically active protein substance |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 98, no. 24, 13 June 1983 (1983-06-13) Columbus, Ohio, US; abstract no. 204391, VIDAL B.C. ET AL.: "Microfibrous and microcrystalline collagen I for use in medicine and pharmacy" XP002170464 cited in the application & BR 8 102 435 A 30 November 1982 (1982-11-30) * |
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 6, 31 July 1995 (1995-07-31) & JP 07 059812 A (KOKEN CO LTD), 7 March 1995 (1995-03-07) & DATABASE WPI Week 199518 Derwent Publications Ltd., London, GB; AN 1995-135943 * |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8603511B2 (en) | 1996-08-27 | 2013-12-10 | Baxter International, Inc. | Fragmented polymeric compositions and methods for their use |
US8303981B2 (en) | 1996-08-27 | 2012-11-06 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US8357378B2 (en) | 1996-08-27 | 2013-01-22 | Baxter International Inc. | Fragmented polymeric compositions and methods for their use |
US8092820B2 (en) | 2001-07-17 | 2012-01-10 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US8383141B2 (en) | 2001-07-17 | 2013-02-26 | Baxter International Inc. | Dry hemostatic compositions and methods for their preparation |
US8834864B2 (en) * | 2003-06-05 | 2014-09-16 | Baxter International Inc. | Methods for repairing and regenerating human dura mater |
US9005609B2 (en) | 2003-08-07 | 2015-04-14 | Ethicon, Inc. | Hemostatic compositions containing sterile thrombin |
US8703122B2 (en) | 2006-05-31 | 2014-04-22 | Baxter International Inc. | Method for directed cell in-growth and controlled tissue regeneration in spinal surgery |
US8962025B2 (en) | 2006-08-02 | 2015-02-24 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US9114172B2 (en) | 2006-08-02 | 2015-08-25 | Baxter International Inc. | Rapidly acting dry sealant and methods for use and manufacture |
US8790698B2 (en) | 2007-10-30 | 2014-07-29 | Baxter International Inc. | Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects |
US9039783B2 (en) | 2009-05-18 | 2015-05-26 | Baxter International, Inc. | Method for the improvement of mesh implant biocompatibility |
US9993298B2 (en) | 2009-05-18 | 2018-06-12 | Baxter International Inc. | Method for the improvement of mesh implant biocompatibility |
US9162006B2 (en) | 2009-06-16 | 2015-10-20 | Baxter International Inc. | Hemostatic sponge |
US11071804B2 (en) | 2009-12-16 | 2021-07-27 | Baxter International Inc. | Hemostatic sponge |
US8771258B2 (en) | 2009-12-16 | 2014-07-08 | Baxter International Inc. | Hemostatic sponge |
US9872934B2 (en) | 2009-12-16 | 2018-01-23 | Baxter International Inc. | Hemostatic sponge |
US9517287B2 (en) | 2009-12-16 | 2016-12-13 | Baxter International, Inc. | Hemostatic sponge |
US8703170B2 (en) | 2010-04-07 | 2014-04-22 | Baxter International Inc. | Hemostatic sponge |
US10441674B2 (en) | 2010-04-07 | 2019-10-15 | Baxter International Inc. | Hemostatic sponge |
US11478566B2 (en) | 2010-04-07 | 2022-10-25 | Baxter International Inc. | Hemostatic sponge |
US9375505B2 (en) | 2010-04-07 | 2016-06-28 | Baxter International Inc. | Hemostatic sponge |
US10245348B2 (en) | 2010-06-01 | 2019-04-02 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9084728B2 (en) | 2010-06-01 | 2015-07-21 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US9408945B2 (en) | 2010-06-01 | 2016-08-09 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US10994045B2 (en) | 2010-06-01 | 2021-05-04 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
US8940335B2 (en) | 2010-06-01 | 2015-01-27 | Baxter International Inc. | Process for making dry and stable hemostatic compositions |
WO2012159635A1 (en) | 2011-05-24 | 2012-11-29 | Nycomed Pharma As | Rolled collagen carrier |
US10532032B2 (en) | 2011-05-24 | 2020-01-14 | Takeda As | Rolled collagen carrier |
MD4471C1 (en) * | 2011-05-24 | 2017-10-31 | Takeda As | Rolled collagen carrier |
US9814686B2 (en) | 2011-05-24 | 2017-11-14 | Takeda As | Rolled collagen carrier |
EP3243489A1 (en) | 2011-05-24 | 2017-11-15 | Takeda AS | Rolled collagen carrier |
US9439999B2 (en) | 2011-07-28 | 2016-09-13 | Harbin Peiqilong Biopharmaceutical Co., Ltd | Composite collagen sponge and preparation method thereof |
US9821025B2 (en) | 2011-10-11 | 2017-11-21 | Baxter International Inc. | Hemostatic compositions |
US10322170B2 (en) | 2011-10-11 | 2019-06-18 | Baxter International Inc. | Hemostatic compositions |
US9833541B2 (en) | 2011-10-27 | 2017-12-05 | Baxter International Inc. | Hemostatic compositions |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
CN104470475B (en) * | 2012-05-24 | 2017-04-19 | 武田有限公司 | Apparatus and process for providing a coiled collagen carrier |
WO2013174879A1 (en) | 2012-05-24 | 2013-11-28 | Takeda Nycomed As | Packaging |
WO2013174874A1 (en) | 2012-05-24 | 2013-11-28 | Takeda Nycomed As | Apparatus and process for providing a coiled collagen carrier |
US10485715B2 (en) | 2012-05-24 | 2019-11-26 | Takeda As | Packaging for form-stable coiled collagen carrier |
CN104470475A (en) * | 2012-05-24 | 2015-03-25 | 武田奈科明有限公司 | Apparatus and process for providing a coiled collagen carrier |
US10213345B2 (en) | 2012-05-24 | 2019-02-26 | Takeda As | Apparatus and process for providing a coiled collagen carrier |
RU2614324C2 (en) * | 2012-05-24 | 2017-03-24 | Такеда Ас | Packaging |
US11000985B2 (en) | 2012-05-24 | 2021-05-11 | Takeda As | Apparatus and process for providing a coiled collagen carrier |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1368419B1 (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
US7098315B2 (en) | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
AU2002249528A1 (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
EP1259269B1 (en) | Agent for the treatment of wounds | |
US20120294823A1 (en) | Method for preparing silk sericin-PVA scaffold using genipin as crosslinking agent | |
WO1999064655A1 (en) | Collagen material and process for producing the same | |
EP3122300A1 (en) | A ready to use biodegradable and biocompatible device and a method of preparation thereof | |
WO1989008465A1 (en) | Medical material permitting cells to enter thereinto and artificial skin | |
CN110639050A (en) | Silk fibroin nanofiber and preparation method of silver-loaded antibacterial dressing based on silk fibroin nanofiber | |
EP0042253B1 (en) | Fibrous collagenous hemostatic-adhesive web and method for its preparation | |
Silverstein et al. | Collagen fibers as a fleece hemostatic agent | |
JP2000060956A (en) | Collagen material and manufacture thereof | |
WO2001066159A1 (en) | Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such | |
US5138030A (en) | Process for extracting type I collagen form an avian source, and applications therefor | |
ZA200305591B (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge. | |
EP1325060B1 (en) | Soybean-based thermoplastics as biomaterials | |
CN115227878B (en) | Silver-loaded type-I collagen composite material and preparation method and application thereof | |
Koller et al. | Biocompatibility studies of modified collagen/Hyaluronan membranes after implantation | |
CN117547657A (en) | Biological adhesive film and preparation method thereof | |
JP2016501270A (en) | Collagen powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2435159 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/05591 Country of ref document: ZA Ref document number: 200305591 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002249528 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 157096 Country of ref document: IL Ref document number: 527166 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/006687 Country of ref document: MX Ref document number: 2002570628 Country of ref document: JP Ref document number: 028040953 Country of ref document: CN Ref document number: 1020037009893 Country of ref document: KR Ref document number: 01165/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002718481 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-2198 Country of ref document: CZ Ref document number: 10362003 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 10812202 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200300821 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037009893 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002718481 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-2198 Country of ref document: CZ |
|
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 37/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION |
|
WWP | Wipo information: published in national office |
Ref document number: 527166 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 527166 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002718481 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002249528 Country of ref document: AU |